Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Symposium dedicated to pulmonary arterial hypertension took place at the 9th Russian Congress on Pulmonary hypertension on December 14, 2021. In this review key points from Chazova I.E., Martynyuk T.V., Valieva Z.S., Gramovich V.V.`s reports are presented, in which information about PAH treatment goals achievement, COVID-19 pandemic challenges impact on routine clinical practice is demonstrated. In this review current situation in pulmonary arterial hypertension treatment goals and regular risk stratification importance are observed, based on the latest clinical trials combined specific therapy including selective prostacyclin receptor agonist selexipag is demonstrated. special attention is paid to pulmonary hypertension patients’ treatment during COVID-19 pandemic, regular risk stratification necessity is mentioned including remote patient monitoring in order to perform timely escalation in PAH-specific treatment in order to achieve low-risk status and to improve the prognosis of PAH patients.

Study objective: to study the incidence of arrhythmias in patients with metabolic syndrome and heart failure in accordance with the severity of the functional class (1964, according to the NYNA classification).

Materials and methods: The study included 90 patients with heart failure (HF) II and III functional class (FC), EF<50% and metabolic syndrome, who received outpatient and inpatient treatment at the J. Abdullaeva Scientific Researh Institute. Among the patients, 57 were with HF II (according to the NYNA classification), and 33 were with HF III functional class. The age of the patients ranged from 36 to 88 years. Of these, 27% were women, 63% were men. The patients underwent complex clinical, instrumental and laboratory examinations. Instrumental examinations included daily monitoring of the electrocardiogram by the Holter method (with CONTEC, TLC 5000), 6-minute walking test, blood ion analysis, MS indicators, and lipid spectrum research. Exclusion criteria were chronic obstructive pulmonary disease, bronchial asthma, cardiomyopathies,heart defects.

Results: The incidence of ventricular premature beats (especially in an amount greater than 1000) among patients with heart failure of the III functional class (97.0%) is slightly higher than in patients of the II functional class (91.2%). However, supraventricular premature beats are more common (78.9%) in patients with functional class II heart failure than in functional class III patients (57.6%). Atrial fibrillation in patients with heart failure of functional class III (33.3%) occurs approximately 1.7 times more often than in patients of functional class II (19.3%). Almost the same frequency of occurrence of episodes of sinus rhythm and atrial fibrillation were observed. Shortterm ventricular tachycardia was recorded in 2 patients of functional class III.

Conclusions: In patients with metabolic syndrome, the incidence of ventricular premature beats and atrial fibrillation correlate with the functional class of heart failure, and episodes of ventricular tachycardia are also observed.

Psoriasis is a genetically determined multifactorial disease that affects about 2% of the population. According to modern concepts of this disease, the level of comorbid diseases, especially those associated with damage to the cardiovascular system, is high. This article presents a clinical case of severe disseminated psoriasis vulgaris, progressive stage, mixed form in a patient with a very high cardiovascular risk. The uniqueness of this clinical case lies in the combined course of psoriasis and such comorbid diseases as: severe hypertension, obesity, dyslipidemia, type 2 diabetes mellitus (DM), hyperuricemia. The main clinical manifestations were the presence of widespread lesions on the patient’s skin, episodes of discomfort behind the sternum during physical activity, as well as destabilization of blood pressure numbers (maximum rise to 180/100 mm Hg). As part of the hospitalization in the skin clinic, the patient underwent topical ointment therapy with the use of glucocorticoid ointments, ointments containing salicylic acid, PUVA therapy, as a result of which the skin process showed positive dynamics with regression of lesions by 90-100% with an outcome in residual hyperpigmentation, no new lesions were noted. During hospitalization to a therapy department, the optimal antihypertensive, lipid-lowering, uricosuric, hypoglycemic therapy was selected, as a result of which it was possible to achieve an improvement in the patient’s condition, stabilization of blood pressure at the level of 130-140/70 mm Hg. So patients with psoriasis require careful assessment of cardiovascular risk in clinical practice. A multidisciplinary approach will not only improve the quality of life of patients, reduce the likelihood of major cardiovascular events, but also increase life expectancy and reduce mortality.

Atrial Fibrillation (AF) is associated with significant increase of stroke and other ischemic events risk. Anticoagulation to prevent ischemic strokes is a critical component of this condition management. Direct oral anticoagulants (DOACs)—with more predictable pharmacokinetics, ease of use and favorable safety and efficacy profile—are the preferred anticoagulants for patients with atrial fibrillation. This retrospective study compares major ischemic and hemorrhagic outcomes in big cohort of patients 65+ y.o. with atrial fibrillation treated with rivaroxaban or apixaban (Ray, W. A. et al., 2021).

An online scientific summit “Hyperuricemia from A to Z” supported by EGIS-RUS LLC was held on December 4, 2021.

The following experts of the Russian Medical Society on Arterial Hypertension (RMSAH) were the speakers and facilitators of the summit: Kislyak O.A., Zhernakova Yu.V., Mironova O.Yu., Blinova N.V., headed by the President of the RMSAH Chazova I.E. as well as a special guest from Italy, Claudio Borghi, Professor, Head of the Department of Cardiovascular Diseases of the University of Bologna. More than 50 experts in the cardiology area from different regions of Russia participated in the summit.

Relevance of the topic is confirmed by the proved association between hyperuricemia cardiovascular mortality.